BMY vs PFE
BMY and PFE side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BMYBristol-Myers Squibb Company | PFEPfizer Inc. |
|---|---|---|
| Market cap | $124.05B | $142.77B |
| P/E (TTM) | 17.0 | 19.1 |
| P/B | 6.18 | 1.58 |
| P/S | 2.6x | 2.3x |
| Dividend yield | — | 6.84% |
| Revenue | $48.48B(TTM) | $63.31B(TTM) |
| Revenue growth (YoY) | -0.2% | -1.6% |
| Net income | $7.28B(TTM) | $7.49B(TTM) |
| Earnings growth (YoY) | 178.8% | -3.2% |
| EPS, diluted | $3.57(TTM) | $1.31(TTM) |
| EBIT margin | 21.8% | 16.3% |
| ROE | 35.2% | 8.6% |
| ROIC | 14.4% | 6.7% |
| Piotroski F | 8/9 | — |
| 1y total return | +31.5% | +8.8% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: BMY vs PFE
| 지표 | BMY | PFE |
|---|---|---|
| 최종 가치 | $13.7K | $13.4K |
| 총수익률 | +37.3% | +33.5% |
| CAGR | +3.1% | +2.8% |
| 변동성 | 25.2% | 23.9% |
| 샤프 | 0.10 | 0.08 |
| 소르티노 | 0.13 | 0.11 |
| 최대 낙폭 | -47.7% | -59.0% |
공통 거래일 2600일 기준, 2016-03-15 → 2026-07-17 · 무위험수익률 3.85% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)